ReviewCurrent opinion in immunology2026
CRAC channels as targets for immunotherapy.
Review in Current opinion in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potassium channels in cancer: from hallmarks to therapeutic targeting.Journal of physiology and biochemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ca²⁺ release-activated Ca²⁺ (CRAC) channels facilitate store-operated Ca²⁺ entry in both immune and nonimmune cells. They are crucial for the function of many immune cell types and strongly associated with the pathophysiology of immune-related disorders. Inherited null mutations in the genes encoding the CRAC channel, ORAI1, and its activator STIM1, are linked to inborn errors of immunity in patients, highlighting the essential role of these channels in immunity. Preclinical studies using knockout mice and CRAC channel inhibitors (CRACi) have further demonstrated their pivotal function in the pathophysiology of immune-related conditions, including immunity to infection, autoimmunity, allergy, and other inflammatory diseases. Clinical trials in patients with inflammatory disorders underscore the potential utility of CRACi for immunotherapy. Here, we provide an overview of CRAC channels in immune cell function, review their roles in preclinical models of immune diseases, and discuss the outcomes of clinical trials involving CRACi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.